(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1350877 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA CTD PMID:22079256 17alpha-ethynylestradiol affects expression ISO RGD:1550507 6480464 Ethinyl Estradiol affects the expression of HSPA4L mRNA CTD PMID:17555576 17alpha-ethynylestradiol multiple interactions ISO RGD:1550507 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of HSPA4L mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression ISO RGD:1550507 6480464 Ethinyl Estradiol results in increased expression of HSPA4L mRNA CTD PMID:17942748 17beta-estradiol increases expression ISO RGD:1350877 6480464 Estradiol results in increased expression of HSPA4L mRNA CTD PMID:20106945 17beta-estradiol multiple interactions ISO RGD:1350877 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of HSPA4L mRNA CTD PMID:30165855 1H-pyrazole increases expression ISO RGD:1550507 6480464 pyrazole results in increased expression of HSPA4L mRNA CTD PMID:17945193 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1550507 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of HSPA4L mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of HSPA4L mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of HSPA4L mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1550507 6480464 Tetrachlorodibenzodioxin results in increased expression of HSPA4L mRNA CTD PMID:18691609 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1550507 6480464 Tetrachlorodibenzodioxin affects the expression of HSPA4L mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1350877 6480464 Tetrachlorodibenzodioxin results in decreased expression of HSPA4L mRNA CTD PMID:20106945 , PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of HSPA4L mRNA CTD PMID:22298810 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of HSPA4L mRNA CTD PMID:21346803 2-butoxyethanol increases expression ISO RGD:1550507 6480464 n-butoxyethanol results in increased expression of HSPA4L mRNA CTD PMID:19812364 3,3',4,4',5-pentachlorobiphenyl increases expression ISO RGD:1550507 6480464 3 more ... CTD PMID:23994337 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1550507 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of HSPA4L mRNA CTD PMID:26251327 4,4'-diaminodiphenylmethane increases expression ISO RGD:1550507 6480464 4, 4'-diaminodiphenylmethane results in increased expression of HSPA4L mRNA CTD PMID:18648102 4-hydroxynon-2-enal increases expression ISO RGD:1550507 6480464 4-hydroxy-2-nonenal results in increased expression of HSPA4L mRNA CTD PMID:19191707 4-hydroxyphenyl retinamide decreases expression ISO RGD:1550507 6480464 Fenretinide results in decreased expression of HSPA4L mRNA CTD PMID:28973697 4-phenylbutyric acid increases expression ISO RGD:1350877 6480464 4-phenylbutyric acid results in increased expression of HSPA4L mRNA CTD PMID:14583596 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of HSPA4L mRNA CTD PMID:24780913 aconitine increases expression EXP 6480464 Aconitine results in increased expression of HSPA4L protein CTD PMID:33236894 acrylamide increases expression ISO RGD:1350877 6480464 Acrylamide results in increased expression of HSPA4L mRNA CTD PMID:32763439 aflatoxin B1 affects expression ISO RGD:1350877 6480464 Aflatoxin B1 affects the expression of HSPA4L protein CTD PMID:20106945 aflatoxin B1 increases expression ISO RGD:1350877 6480464 Aflatoxin B1 results in increased expression of HSPA4L mRNA CTD PMID:21641981 more ... aflatoxin B1 increases expression ISO RGD:1550507 6480464 Aflatoxin B1 results in increased expression of HSPA4L mRNA CTD PMID:19770486 aflatoxin M1 decreases expression ISO RGD:1350877 6480464 Aflatoxin M1 results in decreased expression of HSPA4L mRNA CTD PMID:30928695 all-trans-retinoic acid increases expression ISO RGD:1350877 6480464 Tretinoin results in increased expression of HSPA4L mRNA CTD PMID:21934132 all-trans-retinoic acid decreases expression ISO RGD:1350877 6480464 Tretinoin results in decreased expression of HSPA4L mRNA CTD PMID:23724009 , PMID:33167477 antirheumatic drug decreases expression ISO RGD:1350877 6480464 Antirheumatic Agents results in decreased expression of HSPA4L mRNA CTD PMID:24449571 aristolochic acid A decreases expression ISO RGD:1350877 6480464 aristolochic acid I results in decreased expression of HSPA4L mRNA CTD PMID:33212167 arsenite(3-) multiple interactions ISO RGD:1550507 6480464 [arsenite co-treated with Benzo(a)pyrene] results in increased expression of HSPA4L mRNA CTD PMID:15894712 arsenite(3-) increases expression ISO RGD:1550507 6480464 arsenite results in increased expression of HSPA4L mRNA CTD PMID:15894712 arsenous acid increases expression ISO RGD:1350877 6480464 Arsenic Trioxide results in increased expression of HSPA4L mRNA CTD PMID:26705709 benzo[a]pyrene multiple interactions ISO RGD:1550507 6480464 [arsenite co-treated with Benzo(a)pyrene] results in increased expression of HSPA4L mRNA, [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] CTD PMID:14625279 , PMID:15894712 benzo[a]pyrene increases expression ISO RGD:1550507 6480464 Benzo(a)pyrene results in increased expression of HSPA4L mRNA CTD PMID:14625279 more ... benzo[a]pyrene increases expression ISO RGD:1350877 6480464 Benzo(a)pyrene results in increased expression of HSPA4L mRNA, Benzo(a)pyrene results in increased expression of HSPA4L protein CTD PMID:20106945 more ... beta-naphthoflavone increases expression ISO RGD:1550507 6480464 beta-Naphthoflavone results in increased expression of HSPA4L mRNA CTD PMID:23994337 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1550507 6480464 Diethylhexyl Phthalate results in decreased expression of HSPA4L mRNA CTD PMID:21318169 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of HSPA4L mRNA CTD PMID:30816183 , PMID:34947998 bisphenol A increases expression ISO RGD:1350877 6480464 bisphenol A results in increased expression of HSPA4L mRNA CTD PMID:29275510 bortezomib increases expression EXP 6480464 Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 Brodifacoum increases expression EXP 6480464 bromfenacoum results in increased expression of HSPA4L protein CTD PMID:28903499 bromobenzene decreases expression EXP 6480464 bromobenzene results in decreased expression of HSPA4L mRNA CTD PMID:32479839 cadmium atom increases expression ISO RGD:1350877 6480464 Cadmium results in increased expression of HSPA4L mRNA CTD PMID:21120746 cadmium dichloride increases expression ISO RGD:1550507 6480464 Cadmium Chloride results in increased expression of HSPA4L mRNA CTD PMID:15501611 caffeine decreases phosphorylation ISO RGD:1350877 6480464 Caffeine results in decreased phosphorylation of HSPA4L protein CTD PMID:35688186 carbamazepine affects expression ISO RGD:1350877 6480464 Carbamazepine affects the expression of HSPA4L mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1550507 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 choline multiple interactions ISO RGD:1550507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene CTD PMID:20938992 chromium(6+) affects expression ISO RGD:1350877 6480464 chromium hexavalent ion affects the expression of HSPA4L mRNA CTD PMID:30690063 ciguatoxin CTX1B affects expression ISO RGD:1550507 6480464 Ciguatoxins affects the expression of HSPA4L mRNA CTD PMID:18353800 cisplatin multiple interactions ISO RGD:1350877 6480464 [Piroxicam co-treated with Cisplatin] results in increased expression of HSPA4L mRNA CTD PMID:21858171 clofibrate increases expression ISO RGD:1550507 6480464 Clofibrate results in increased expression of HSPA4L mRNA CTD PMID:23811191 copper(II) sulfate decreases expression ISO RGD:1350877 6480464 Copper Sulfate results in decreased expression of HSPA4L mRNA CTD PMID:19549813 coumestrol increases expression ISO RGD:1350877 6480464 Coumestrol results in increased expression of HSPA4L mRNA CTD PMID:19167446 coumestrol multiple interactions ISO RGD:1350877 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA CTD PMID:19167446 cyclosporin A increases expression ISO RGD:1350877 6480464 Cyclosporine results in increased expression of HSPA4L mRNA CTD PMID:20106945 cyclosporin A decreases expression ISO RGD:1350877 6480464 Cyclosporine results in decreased expression of HSPA4L mRNA CTD PMID:27989131 cyclosporin A affects expression ISO RGD:1350877 6480464 Cyclosporine affects the expression of HSPA4L mRNA CTD PMID:25562108 diarsenic trioxide increases expression ISO RGD:1350877 6480464 Arsenic Trioxide results in increased expression of HSPA4L mRNA CTD PMID:26705709 dibenz[a,h]anthracene decreases expression ISO RGD:1550507 6480464 1 more ... CTD PMID:26377693 dibenzo[a,l]pyrene decreases expression ISO RGD:1550507 6480464 dibenzo(a, l)pyrene results in decreased expression of HSPA4L mRNA CTD PMID:25908611 dimethylarsinic acid multiple interactions ISO RGD:1550507 6480464 OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA4L mRNA] CTD PMID:17441966 dimethylarsinic acid decreases expression ISO RGD:1550507 6480464 Cacodylic Acid results in decreased expression of HSPA4L mRNA CTD PMID:17441966 dioxygen decreases expression EXP 6480464 Oxygen deficiency results in decreased expression of HSPA4L mRNA CTD PMID:26476374 dioxygen multiple interactions EXP 6480464 Quercetin inhibits the reaction [Oxygen deficiency results in decreased expression of HSPA4L mRNA] CTD PMID:26476374 dorsomorphin multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin affects expression ISO RGD:1350877 6480464 Doxorubicin affects the expression of HSPA4L mRNA CTD PMID:25529476 doxorubicin decreases expression EXP 6480464 Doxorubicin results in decreased expression of HSPA4L mRNA CTD PMID:30261314 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of HSPA4L mRNA CTD PMID:29391264 Enterolactone multiple interactions ISO RGD:1350877 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA CTD PMID:19167446 entinostat multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 entinostat increases expression ISO RGD:1350877 6480464 entinostat results in increased expression of HSPA4L mRNA CTD PMID:26272509 enzyme inhibitor multiple interactions ISO RGD:1350877 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of HSPA4L protein CTD PMID:23301498 epoxiconazole decreases expression ISO RGD:1550507 6480464 epoxiconazole results in decreased expression of HSPA4L mRNA CTD PMID:35436446 ethanol multiple interactions ISO RGD:1350877 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of HSPA4L mRNA CTD PMID:23378141 ethanol affects splicing ISO RGD:1550507 6480464 Ethanol affects the splicing of HSPA4L mRNA CTD PMID:30319688 ethanol increases expression ISO RGD:1350877 6480464 Ethanol results in increased expression of HSPA4L mRNA CTD PMID:23378141 , PMID:28986285 fenofibrate increases expression ISO RGD:1550507 6480464 Fenofibrate results in increased expression of HSPA4L mRNA CTD PMID:21318169 fenofibrate multiple interactions ISO RGD:1550507 6480464 PPARA protein affects the reaction [Fenofibrate results in increased expression of HSPA4L mRNA] CTD PMID:21318169 fenvalerate decreases expression EXP 6480464 fenvalerate results in decreased expression of HSPA4L protein CTD PMID:33656234 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of HSPA4L mRNA CTD PMID:24793618 folic acid multiple interactions ISO RGD:1550507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene CTD PMID:20938992 folic acid multiple interactions ISO RGD:1350877 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of HSPA4L mRNA CTD PMID:23378141 furan increases expression ISO RGD:1550507 6480464 furan results in increased expression of HSPA4L mRNA CTD PMID:24183702 furan increases expression EXP 6480464 furan results in increased expression of HSPA4L mRNA CTD PMID:25539665 genistein increases expression ISO RGD:1350877 6480464 Genistein results in increased expression of HSPA4L mRNA CTD PMID:18847459 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of HSPA4L mRNA CTD PMID:22061828 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of HSPA4L mRNA CTD PMID:33387578 hydrogen cyanide increases expression ISO RGD:1550507 6480464 Hydrogen Cyanide results in increased expression of HSPA4L mRNA CTD PMID:33914522 hydrogen sulfide decreases expression ISO RGD:1550507 6480464 Hydrogen Sulfide results in decreased expression of HSPA4L protein CTD PMID:29932956 irinotecan decreases expression ISO RGD:1350877 6480464 Irinotecan metabolite results in decreased expression of HSPA4L mRNA, Irinotecan results in decreased expression of HSPA4L mRNA CTD PMID:15956246 ivermectin decreases expression ISO RGD:1350877 6480464 Ivermectin results in decreased expression of HSPA4L protein CTD PMID:32959892 L-methionine multiple interactions ISO RGD:1550507 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of HSPA4L gene CTD PMID:20938992 leflunomide increases expression ISO RGD:1350877 6480464 leflunomide results in increased expression of HSPA4L mRNA CTD PMID:28988120 manganese(II) chloride increases expression EXP 6480464 manganese chloride results in increased expression of HSPA4L mRNA CTD PMID:28801915 mercury dibromide increases expression ISO RGD:1350877 6480464 mercuric bromide results in increased expression of HSPA4L mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 mercury dichloride increases expression EXP 6480464 Mercuric Chloride results in increased expression of HSPA4L mRNA CTD PMID:16507785 methidathion decreases expression ISO RGD:1550507 6480464 methidathion results in decreased expression of HSPA4L mRNA CTD PMID:34813904 methyl methanesulfonate increases expression ISO RGD:1350877 6480464 Methyl Methanesulfonate results in increased expression of HSPA4L mRNA CTD PMID:23649840 methylisothiazolinone increases expression ISO RGD:1350877 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of HSPA4L mRNA CTD PMID:31629900 methylmercury chloride increases expression ISO RGD:1350877 6480464 methylmercuric chloride results in increased expression of HSPA4L mRNA CTD PMID:28001369 methylseleninic acid increases expression ISO RGD:1350877 6480464 methylselenic acid results in increased expression of HSPA4L mRNA CTD PMID:18548127 motexafin gadolinium increases expression ISO RGD:1350877 6480464 motexafin gadolinium results in increased expression of HSPA4L mRNA CTD PMID:16357179 motexafin gadolinium multiple interactions ISO RGD:1350877 6480464 [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA CTD PMID:16357179 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of HSPA4L mRNA CTD PMID:28801915 N-nitrosodiethylamine increases expression ISO RGD:1550507 6480464 Diethylnitrosamine results in increased expression of HSPA4L mRNA CTD PMID:24535843 Nonidet P-40 increases expression ISO RGD:1350877 6480464 Nonidet P-40 results in increased expression of HSPA4L mRNA CTD PMID:26552463 p-chloromercuribenzoic acid increases expression ISO RGD:1350877 6480464 p-Chloromercuribenzoic Acid results in increased expression of HSPA4L mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1350877 6480464 panobinostat results in increased expression of HSPA4L mRNA CTD PMID:26272509 panobinostat multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 paracetamol increases expression ISO RGD:1350877 6480464 Acetaminophen results in increased expression of HSPA4L mRNA CTD PMID:21420995 more ... paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of HSPA4L mRNA CTD PMID:33387578 phenformin decreases expression EXP 6480464 Phenformin results in decreased expression of HSPA4L mRNA CTD PMID:31324951 phenobarbital multiple interactions ISO RGD:1550507 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of HSPA4L mRNA] CTD PMID:19482888 phenobarbital affects expression ISO RGD:1550507 6480464 Phenobarbital affects the expression of HSPA4L mRNA CTD PMID:23091169 phenobarbital increases expression ISO RGD:1550507 6480464 Phenobarbital results in increased expression of HSPA4L mRNA CTD PMID:19482888 phenylmercury acetate increases expression ISO RGD:1350877 6480464 Phenylmercuric Acetate results in increased expression of HSPA4L mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 pirinixic acid multiple interactions ISO RGD:1550507 6480464 PPARA protein affects the reaction [pirinixic acid results in increased expression of HSPA4L mRNA], PPARA protein promotes the reaction [pirinixic acid results in increased expression of HSPA4L mRNA] CTD PMID:20059764 , PMID:21318169 pirinixic acid increases expression ISO RGD:1550507 6480464 pirinixic acid results in increased expression of HSPA4L mRNA CTD PMID:18301758 more ... piroxicam multiple interactions ISO RGD:1350877 6480464 [Piroxicam co-treated with Cisplatin] results in increased expression of HSPA4L mRNA CTD PMID:21858171 potassium chromate multiple interactions ISO RGD:1550507 6480464 [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] CTD PMID:14625279 potassium chromate increases expression ISO RGD:1350877 6480464 potassium chromate(VI) results in increased expression of HSPA4L mRNA CTD PMID:22714537 potassium chromate multiple interactions ISO RGD:1350877 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1350877 6480464 potassium chromate(VI) results in decreased expression of HSPA4L mRNA CTD PMID:22079256 potassium cyanide increases expression ISO RGD:1550507 6480464 Potassium Cyanide results in increased expression of HSPA4L mRNA CTD PMID:33914522 potassium dichromate multiple interactions ISO RGD:1550507 6480464 [Potassium Dichromate co-treated with potassium chromate(VI)] inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA4L mRNA] CTD PMID:14625279 progesterone affects expression ISO RGD:1550507 6480464 Progesterone affects the expression of HSPA4L mRNA CTD PMID:17251523 propiconazole increases expression ISO RGD:1550507 6480464 propiconazole results in increased expression of HSPA4L mRNA CTD PMID:21278054 propiconazole increases expression EXP 6480464 propiconazole results in increased expression of HSPA4L mRNA CTD PMID:16643972 quercetin multiple interactions EXP 6480464 Quercetin inhibits the reaction [Oxygen deficiency results in decreased expression of HSPA4L mRNA] CTD PMID:26476374 quercetin decreases expression ISO RGD:1350877 6480464 Quercetin results in decreased expression of HSPA4L mRNA CTD PMID:21632981 resorcinol decreases expression ISO RGD:1350877 6480464 resorcinol results in decreased expression of HSPA4L mRNA CTD PMID:22623647 resveratrol increases expression ISO RGD:1550507 6480464 resveratrol results in increased expression of HSPA4L protein CTD PMID:25505154 retinyl acetate increases expression ISO RGD:1550507 6480464 retinol acetate results in increased expression of HSPA4L mRNA CTD PMID:16772331 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of HSPA4L mRNA CTD PMID:28374803 SB 431542 multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silver atom increases expression ISO RGD:1350877 6480464 Silver results in increased expression of HSPA4L mRNA CTD PMID:26014281 , PMID:28959546 silver(0) increases expression ISO RGD:1350877 6480464 Silver results in increased expression of HSPA4L mRNA CTD PMID:26014281 , PMID:28959546 sodium arsenite increases expression ISO RGD:1550507 6480464 sodium arsenite results in increased expression of HSPA4L mRNA CTD PMID:16014739 sodium arsenite increases expression ISO RGD:1350877 6480464 sodium arsenite results in increased expression of HSPA4L mRNA CTD PMID:26535918 , PMID:34032870 tamoxifen affects expression ISO RGD:1550507 6480464 Tamoxifen affects the expression of HSPA4L mRNA CTD PMID:17555576 , PMID:20937368 temozolomide increases expression ISO RGD:1350877 6480464 Temozolomide results in increased expression of HSPA4L mRNA CTD PMID:31758290 tetrachloromethane increases expression ISO RGD:1550507 6480464 Carbon Tetrachloride results in increased expression of HSPA4L mRNA CTD PMID:27339419 , PMID:31919559 thimerosal increases expression ISO RGD:1350877 6480464 Thimerosal results in increased expression of HSPA4L mRNA CTD PMID:27188386 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of HSPA4L mRNA CTD PMID:23411599 , PMID:34492290 titanium dioxide decreases expression ISO RGD:1550507 6480464 titanium dioxide results in decreased expression of HSPA4L mRNA CTD PMID:23557971 triadimefon decreases expression EXP 6480464 triadimefon results in decreased expression of HSPA4L mRNA CTD PMID:16643972 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of HSPA4L mRNA CTD PMID:33387578 trichostatin A increases expression ISO RGD:1350877 6480464 trichostatin A results in increased expression of HSPA4L mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 Triptolide affects expression ISO RGD:1550507 6480464 triptolide affects the expression of HSPA4L mRNA CTD PMID:32835833 triptonide decreases expression ISO RGD:1550507 6480464 triptonide results in decreased expression of HSPA4L mRNA CTD PMID:33045310 troglitazone increases expression ISO RGD:1550507 6480464 troglitazone results in increased expression of HSPA4L mRNA CTD PMID:28973697 tungsten decreases expression ISO RGD:1550507 6480464 Tungsten results in decreased expression of HSPA4L mRNA CTD PMID:30912803 urethane increases expression ISO RGD:1350877 6480464 Urethane results in increased expression of HSPA4L mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1550507 6480464 Valproic Acid affects the expression of HSPA4L mRNA CTD PMID:17963808 valproic acid multiple interactions ISO RGD:1350877 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1350877 6480464 Valproic Acid results in increased expression of HSPA4L mRNA CTD PMID:23179753 more ... valproic acid affects expression ISO RGD:1350877 6480464 Valproic Acid affects the expression of HSPA4L mRNA CTD PMID:25979313 vinclozolin decreases expression ISO RGD:1550507 6480464 vinclozolin results in decreased expression of HSPA4L mRNA CTD PMID:18940246 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of HSPA4L mRNA CTD PMID:23034163 vorinostat increases expression ISO RGD:1350877 6480464 vorinostat results in increased expression of HSPA4L mRNA CTD PMID:27188386 zinc acetate multiple interactions ISO RGD:1350877 6480464 [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA CTD PMID:16357179 zinc acetate increases expression ISO RGD:1350877 6480464 Zinc Acetate results in increased expression of HSPA4L mRNA CTD PMID:16357179 zinc atom multiple interactions ISO RGD:1350877 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of HSPA4L mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1350877 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of HSPA4L mRNA CTD PMID:18593933